Navigation Links
Immunotherapy-Based Provisional Patents Mark Significant Discovery

Quantum Immunologics announces the filing of two important provisional patent applications

TAMPA, Fla., March 31 /PRNewswire/ -- Quantum Immunologics, Inc. (QI), a Florida-based company specializing in cancer immunotherapy, has recently filed two provisional patent applications relating to their work in cancer immunotherapy.

The company's research is focused on the use of the oncofetal antigen ("OFA"), or more specifically, iLRP - immature Laminin Receptor Protein, as a cancer immunogen (a cancer target against which the immune system is directed) found in many tumor cell lines or fetal tissue, but not found in normal mature tissue. This makes it a unique target for personalized anti-cancer therapy for multiple cancers. The company is currently conducting clinical trials using OFA/iLRP as an immunogen in Stage IV breast cancer patients. The FDA-approved trial involves using the body's own immune cells, i.e., the dendritic cells, to recognize OFA/iLRP as a foreign protein and to have them direct the immune system against the cancer cells.

The first patent application describes the discovery of protein sequences, known as a peptides, found on the OFA/iLRP protein that are thought to be more immunogenic and more specific than the OFA/iLRP protein as a whole. With the discovery of these sequences, QI believes that dendritic cell recognition of the foreign cancer protein can be more efficient and specific, and will therefore result in a more effective immunotherapy treatment against malignancy. Additionally, QI researchers believe that it may also be possible to someday inoculate patients directly with the peptides as a direct immunogen to create immunity against cancer without the use of dendritic cells.

The second patent relates to antibodies discovered against these specific peptides. Antibodies are proteins made by the B cells of the body's immune system to aid in the recognition and destruction of foreign materials including cancer cells. Because they have a strong affinity for specific regions in proteins found on cancer cells (OFA/iLRP peptides), these antibodies have diagnostic and therapeutic uses. From a diagnostic standpoint, tests can be created to diagnose the presence or location of cancer in serum or in tissue by the addition of marker substances to the antibodies. From a therapeutic standpoint, these antibodies, once prepared for human use, may possibly be used as a therapy against the cancer (passive immunity), or if joined with materials toxic to cancer cells or by altering the structure of the antibody, provide a more effective and direct therapy to destroy cancer cells while sparing normal tissue.

With these new discoveries, QI has improved its pipeline and intellectual property portfolio and hopes to promote its goals of providing effective anti-cancer therapy with minimal side effects, and to design effective methods for the earlier detection of cancers. Research is presently being planned and conducted to advance these discoveries to promote their use within clinical settings.

About Quantum Immunologics

Quantum Immunologics, Inc. ("QI") is a research-driven biotechnology company that is pioneering discoveries in immunotherapy science. QI is dedicated to the research, development and production of technologies that focus on the treatments and diagnoses of cancer and other diseases related to the immune system. Leveraging an expansive pipeline of biopharmaceutical innovations, QI remains committed to advancing medicine with the ultimate goal of dramatically improving lives. QI is currently involved in Phase I/II FDA clinical trials in Mobile, Alabama, for patients with stage IV breast cancer. For more information about the company, visit

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include, but are not limited to, statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Quantum Immunologics, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


    Barry Rooth
    Corporate Affairs


    Timothy Schwiers
    Investor Relations

    Quantum Immunologics, Inc.
    3000 Bayport Dr. Suite 910
    PO Box 20727
    Tampa, FL 33623-0727

This release was issued through eReleases(TM). For more information, visit

SOURCE Quantum Immunologics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
2. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
3. iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology
4. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
5. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
6. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
7. U.S. PTO Reexamining Lumenis Patents
8. Mercury Therapeutics Patents Filed
9. Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
10. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
11. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing of ... team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn ...
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):